Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Fineline Cube Apr 30, 2026
Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Fineline Cube Apr 29, 2026
Company Deals

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Fineline Cube Apr 29, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer

Fineline Cube Apr 30, 2026
Company Drug

Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer

Fineline Cube Apr 30, 2026
Company Drug

European Commission Grants Conditional Approval for Janssen’s Talvey in Multiple Myeloma

Fineline Cube Aug 23, 2023

The European Commission (EC) has granted conditional approval to Johnson & Johnson’s (J&J; NYSE: JNJ)...

Company Drug

Jiangsu Hengrui Pharmaceuticals’ Fluzoparib Files for New Indication with China’s NMPA

Fineline Cube Aug 23, 2023

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that the National Medical Products...

Company Drug

Kintor Pharmaceutical Completes Enrollment in Phase II Study of GT20029 for Androgenetic Alopecia

Fineline Cube Aug 23, 2023

China-based Kintor Pharmaceutical Limited (HKG: 9939) has announced the completion of patient enrollment in a...

Company Drug

Novartis’s Leqvio (Inclisiran) Approved in China for Hypercholesterolemia Treatment

Fineline Cube Aug 23, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has received approval from the National Medical Products Administration...

Company Drug

Novatim’s KQ-2003 and KY-0118 Advance with Clinical Trial Approvals in China

Fineline Cube Aug 22, 2023

China-based cancer immunotherapy specialist Novatim Immune Therapeutics (Zhejiang) Co., Ltd has recently obtained clinical trial...

Company Drug

Sichuan Huiyu Pharmaceutical’s Plerixafor Gains Marketing Approval from Italian Medicines Agency

Fineline Cube Aug 22, 2023

Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a China-based pharmaceutical company, has announced that it...

Company Medical Device

Lifetech Scientific Corporation Receives NMPA Approval for Epione Navigation System

Fineline Cube Aug 22, 2023

China-based Lifetech Scientific Corporation (HKG: 1302) has announced that it has received market approval from...

Company Deals

Jiahui Health and Gleneagles Hong Kong Hospital Partner for Integrated Healthcare Services

Fineline Cube Aug 22, 2023

China-based Jiahui Health has entered into a strategic partnership with Gleneagles Hong Kong Hospital to...

Company Deals

Saints Sages Surgical Secures Series B Funding to Advance Energy-Based Devices

Fineline Cube Aug 22, 2023

Shanghai-based Saints Sages Surgical Co., Ltd, a leading developer of high-value minimally invasive surgical products,...

Company Drug

Hainan Huluwa Pharmaceutical Gets NMPA Approval for Generic Briviact Clinical Study

Fineline Cube Aug 22, 2023

China-based Hainan Huluwa Pharmaceutical Group Co., Ltd (SHA: 605199) has announced that it has received...

Company Deals

CSPC Pharmaceutical Group Partners with Insilico and XtalPi for AI-Driven Drug R&D

Fineline Cube Aug 22, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced strategic partnership agreements with Insilico Medicine...

Company Drug

Luye Pharma Group Submits Market Approval Filing for Lurbinectedin in Metastatic SCLC in Macau

Fineline Cube Aug 22, 2023

China-based Luye Pharma Group (HKG: 2186) has announced that a market approval filing has been...

Company Medical Device

magAssist Receives FDA Breakthrough Device Designation for NyokAssist VAD

Fineline Cube Aug 22, 2023

magAssist, a firm based in Suzhou, China, has announced that it has received breakthrough device...

Company Drug

Auzone Biological Technology Gets FDA Approval for Edaravone Oral Preparations in ALS

Fineline Cube Aug 22, 2023

Suzhou Auzone Biological Technology Co., Ltd. has received approval from the US Food and Drug...

Company

RemeGen Ltd Reports 20.56% YOY Revenue Growth in H1 2023 Financial Results

Fineline Cube Aug 22, 2023

China-based RemeGen Ltd (SHA: 688331, HKG: 9995) has released its financial report for the first...

Company Drug

Gilead’s Magrolimab Phase III Trial for AML Faces Partial Hold by FDA

Fineline Cube Aug 22, 2023

Gilead (NASDAQ: GILD) has announced that the US Food and Drug Administration (FDA) has imposed...

Company

Ascentage Pharma’s 2023 Interim Report: 49% YOY Revenue Growth and Market Expansion

Fineline Cube Aug 22, 2023

China-based Ascentage Pharma (HKG: 6855) has released its 2023 interim financial report, revealing a 49%...

Company Drug

Pfizer’s RSV Vaccine Abrysvo Receives FDA Authorization for Maternal Immunization

Fineline Cube Aug 22, 2023

The US Food and Drug Administration (FDA) has authorized the use of Pfizer’s (NYSE: PFE)...

Company Drug

J&J’s Teclistamab Granted Priority Review in China for Relapsed Multiple Myeloma

Fineline Cube Aug 22, 2023

The Center for Drug Evaluation (CDE) website has indicated that Johnson & Johnson’s (J&J, NYSE:...

Company

Ascletis Pharma Inc. Reports 21.7% Revenue Increase in H1 2023, Led by Ritonavir Sales

Fineline Cube Aug 22, 2023

China-based Ascletis Pharma Inc., (HKG: 1672) has revealed revenues of RMB 46.51 million (USD 6.38...

Posts pagination

1 … 479 480 481 … 660

Recent updates

  • BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer
  • Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength
  • Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer
  • Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam
  • AbbVie Reports 12.4% Revenue Growth in Q1 2026 Driven by Immunology and Neuroscience Strength
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer

Company

Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength

Company Drug

Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer

Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.